Kanada - Inggeris - Health Canada

grifols therapeutics llc - albumin (human) - solution - 25% - albumin (human) 25% - blood derivatives

Kanada - Inggeris - Health Canada

octapharma pharmazeutika produktionsges m b h - albumin (human) - solution - 25% - albumin (human) 25% - blood derivatives

Kanada - Inggeris - Health Canada

csl behring canada inc - albumin (human) - solution - 25% - albumin (human) 25% - blood derivatives

Kanada - Inggeris - Health Canada

alberta veterinary laboratories ltd - sulfamethazine sodium - solution - 25% - sulfamethazine sodium 25% - cattle; swine (pigs); poultry; horses; sheep

Amerika Syarikat - Inggeris - NLM (National Library of Medicine)

stiefel laboratories inc - acitretin (unii: lch760e9t7) (acitretin - unii:lch760e9t7) - acitretin 10 mg - soriatane is indicated for the treatment of severe psoriasis in adults. because of significant adverse effects associated with its use, soriatane should be prescribed only by those knowledgeable in the systemic use of retinoids. in females of reproductive potential, soriatane should be reserved for non-pregnant patients who are unresponsive to other therapies or whose clinical condition contraindicates the use of other treatments (see boxed contraindications and warnings — soriatane can cause severe birth defects). most patients experience relapse of psoriasis after discontinuing therapy. subsequent courses, when clinically indicated, have produced efficacy results similar to the initial course of therapy. see boxed contraindications and warnings. soriatane is contraindicated in patients with severely impaired liver or kidney function and in patients with chronic abnormally elevated blood lipid values (see boxed warnings:hepatotoxicity, warnings:lipids and possible cardiovascular effects, and precautions). an

Amerika Syarikat - Inggeris - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - mycophenolate mofetil (unii: 9242ecw6r0) (mycophenolic acid - unii:hu9dx48n0t) - mycophenolate mofetil 250 mg - mycophenolate mofetil (mmf) is indicated for the prophylaxis of organ rejection, in adult and pediatric recipients 3 months of age and older of allogeneic kidney [see clinical studies ( 14.1)] , heart [see clinical studies ( 14.2)] or liver transplants [see clinical studies ( 14.3)] , in combination with other immunosuppressants . allergic reactions to mycophenolate mofetil have been observed; therefore, mycophenolate mofetil is contraindicated in patients with a hypersensitivity to mycophenolate mofetil (mmf), mycophenolic acid (mpa) or any component of the drug product. pregnancy exposure registry: there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to mycophenolate during pregnancy and those becoming pregnant within 6 weeks of discontinuing mycophenolate mofetil treatment. to report a pregnancy or obtain information about the registry, visit www.mycophenolaterems.com or call 1-800-617-8191. risk summary: use of mycophenolate mofetil (mmf) during pregnancy is asso

Amerika Syarikat - Inggeris - NLM (National Library of Medicine)

american health packaging - sirolimus (unii: w36zg6ft64) (sirolimus - unii:w36zg6ft64) - sirolimus 0.5 mg - sirolimus tablets are indicated for the prophylaxis of organ rejection in patients aged 13 years or older receiving renal transplants. in patients at low- to moderate-immunologic risk, it is recommended that sirolimus tablets be used initially in a regimen with cyclosporine and corticosteroids; cyclosporine should be withdrawn 2 to 4 months after transplantation [see dosage and administration ( 2.2)]. in patients at high-immunologic risk (defined as black recipients and/or repeat renal transplant recipients who lost a previous allograft for immunologic reason and/or patients with high panel-reactive antibodies [pra; peak pra level > 80%]), it is recommended that sirolimus tablets be used in combination with cyclosporine and corticosteroids for the first year following transplantation [see dosage and administration ( 2.3), clinical studies ( 14.3)]. cyclosporine withdrawal has not been studied in patients with banff grade 3 acute rejection or vascular rejection prior to cyclosporine withdrawal, those who are

Amerika Syarikat - Inggeris - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - calcitriol (unii: fxc9231jvh) (calcitriol - unii:fxc9231jvh) - calcitriol 0.25 ug - calcitriol is indicated in the management of secondary hyperparathyroidism and resultant metabolic bone disease in patients with moderate to severe chronic renal failure (ccr 15 to 55 ml/min) not yet on dialysis. in children, the creatinine clearance value must be corrected for a surface area of 1.73 square meters. a serum ipth level of ≥100 pg/ml is strongly suggestive of secondary hyperparathyroidism. calcitriol is indicated in the management of hypocalcemia and the resultant metabolic bone disease in patients undergoing chronic renal dialysis. in these patients, calcitriol administration enhances calcium absorption, reduces serum alkaline phosphatase levels, and may reduce elevated parathyroid hormone levels and the histological manifestations of osteitis fibrosa cystica and defective mineralization. calcitriol is also indicated in the management of hypocalcemia and its clinical manifestations in patients with postsurgical hypoparathyroidism, idiopathic hypoparathyroidism, and pseudohypoparathyroidism. calcitriol capsules should not be given to patients with hypercalcemia or evidence of vitamin d toxicity. use of calcitriol in patients with known hypersensitivity to calcitriol (or drugs of the same class) or any of the inactive ingredients is contraindicated.

Amerika Syarikat - Inggeris - NLM (National Library of Medicine)

ritedose pharmaceuticals, llc - albuterol sulfate (unii: 021sef3731) (albuterol - unii:qf8svz843e) - albuterol 2.5 mg in 3 ml - albuterol sulfate inhalation solution is indicated for the relief of bronchospasm in patients 2 years of age and older with reversible obstructive airway disease and acute attacks of bronchospasm. albuterol sulfate inhalation solution is contraindicated in patients with a history of hypersensitivity to any of its components. albuterol sulfate inhalation solution 0.083% 3 note: this is a unit-dose vial. no dilution is required. read complete instructions carefully before using. - remove the vial from the foil pouch. - twist the cap completely off the vial and squeeze the contents into the nebulizer reservoir (figure 1). - connect the nebulizer reservoir to the mouthpiece or face mask (figure 2). - connect the nebulizer to the compressor. - sit in a comfortable, upright position; place the mouthpiece in your mouth (figure 3) (or put on the face mask); and turn on the compressor. - breathe as calmly, deeply and evenly as possible until no more mist is formed in the nebulizer chamber (about 5 to 15 minutes). at this point, the treatment is finished. - clean the nebulizer (see manufacturer's instructions). note: use only as directed by your physician. more frequent administration or higher doses are not recommended . store albuterol sulfate inhalation solution 0.083% 3 between 2° and 25° c (36° and 77° f). store in pouch until time of use. additional instructions: manufactured by: the ritedose corporation columbia, sc 29203 for ritedose pharmaceuticals, llc columbia, sc 29203 to report suspected adverse reactions, contact ritedose pharmaceuticals, llc at 1-855-806-3300 or fda at 1-800-fda-1088 or www.fda.gov/medwatch rpin0052 march 2014

Amerika Syarikat - Inggeris - NLM (National Library of Medicine)

hikma pharmaceutical - ciprofloxacin hydrochloride (unii: 4ba73m5e37) (ciprofloxacin - unii:5e8k9i0o4u) - ciprofloxacin 250 mg - ciprofloxacin tablets, usp are indicated for the treatment of infections caused by susceptible isolates of the designated microorganisms in the conditions and patient populations listed below. please see dosage and administration for specific recommendations. urinary tract infections caused by escherichia coli , klebsiella pneumoniae , enterobacter cloacae , serratia marcescens , proteus mirabilis , providencia rettgeri , morganella morganii , citrobacter koseri (diversus) , citrobacter freundii , pseudomonas aeruginosa , methicillin-susceptible staphylococcus epidermidis , staphylococcus saprophyticus , or vancomycin-susceptible enterococcus faecalis . acute uncomplicated cystitis in females caused by escherichia coli or staphylococcus saprophyticus. chronic bacterial prostatitis caused by escherichia coli or proteus mirabilis. lower respiratory tract infections caused by escherichia coli, klebsiella pneumoniae, enterobacter cloacae, proteus mirabilis, pseudomonas aeruginosa, haemophilus influenzae, h